NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-05-26 Financing
Non-offering prospectus product supplement – English.pdf
Results 2026-05-26
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
News release - English.pdf
Transactions 2026-05-22 Financing
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Transactions 2026-05-22 Financing
Underwriting or agency agreements (or amendment thereto).pdf
Transactions 2026-05-22 Financing
Amendment to (or amended) final short form prospectus – English.pdf
Transactions 2026-05-22 Financing
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
News release - English.pdf
Transactions 2026-05-21 Financing
Draft shelf prospectus supplement – English.pdf
Transactions 2026-05-21 Financing
NervGen Announces Proposed Public Offering of Securities
News release - English.pdf
Results 2026-05-18
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
News release - English.pdf
Results 2026-05-15
Interim financial statements/report – English.pdf
Results 2026-05-15
Interim MD&A - English.pdf
Ownership 2026-05-04
Punnett, Harold bought +$16k
Insider trading – 2026-05-04
1 insider · +$16k net
Ownership 2026-04-24
Other securityholders documents - English.pdf
Results 2026-04-07
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
News release - English.pdf
Results 2026-03-31
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
News release - English.pdf
Results 2026-03-31
Annual information form - English.pdf
Results 2026-03-31
Annual MD&A - English.pdf
Results 2026-03-31
Audited annual financial statements – English.pdf
Ownership 2026-03-13
McKerracher, Krista sold +$20k
Insider trading – 2026-03-13
1 insider · −$20k net
Ownership 2026-03-02
McKerracher, Krista sold +$80k
Insider trading – 2026-03-02
1 insider · −$80k net
Ownership 2026-02-23
McKerracher, Krista sold +$126k
Insider trading – 2026-02-23
1 insider · −$126k net
Ownership 2026-02-16
McKerracher, Krista sold +$40k
Insider trading – 2026-02-16
1 insider · −$40k net
News 2026-02-13
Other.pdf
News 2026-02-12
Other.pdf
News 2025-12-30
Early warning report.pdf
News 2025-12-16
Decision Document (First Amendment to Final).pdf
Transactions 2025-12-15 Financing
Amendment to (or amended) final short form prospectus – English.pdf
Transactions 2025-12-13 Financing
NervGen Pharma Announces Proposed Amendment to Warrants
News release - English.pdf
Ownership 2025-12-09
McKerracher, Krista bought +$4k
Insider trading – 2025-12-09
1 insider · +$4k net
News 2025-12-01
Report of exempt distribution (45-106F1) (amended).pdf
News 2025-11-28
Report of exempt distribution (45-106F1).pdf
Transactions 2025-11-26 Financing
NervGen Pharma Corp. Closes Non-Brokered Unit Offering for Aggregate Gross Proceeds of US$10,049,915
Material change report - English.pdf
Results 2025-11-24
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
News release - English.pdf
Results 2025-11-24 Financials
Interim MD&A - English.pdf
Results 2025-11-24 Financials
Interim financial statements/report – English.pdf
Results 2025-11-24
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
News release - English.pdf
News 2025-11-21
Early warning report.pdf
Ownership 2025-11-20
Bayley, Brian Eric bought +$525k
Insider trading – 2025-11-20
1 insider · +$525k net
Transactions 2025-11-19 Financing
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
News release - English.pdf
Ownership 2025-11-19
Rogers, Adam bought +$3.8M
Insider trading – 2025-11-19
1 insider · +$3.8M net
Transactions 2025-11-18 Financing
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
News release - English.pdf
News 2025-08-26
News release - English.pdf
Results 2025-08-26 Financials
Interim MD&A - English.pdf
Results 2025-08-26 Financials
Interim financial statements/report – English.pdf
News 2025-08-21
News release - English.pdf
News 2025-07-25
Material change report - English.pdf
News 2025-07-17
News release - English.pdf
News 2025-07-07
News release - English.pdf
News 2025-07-07
Material change report - English.pdf
News 2025-07-03
News release - English.pdf
News 2025-07-01
News release - English.pdf
News 2025-06-18
News release - English.pdf
News 2025-06-02
Material change report - English.pdf
News 2025-06-02
News release - English.pdf